Phenotypes Associated with This Genotype

Genotype
MGI:3814236

• Allelic Composition: Ar^tm4(AR)Dmr/Ar⁺
• Genetic Background: involves: 129S1/Sv * C57BL/6J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

mortality/aging ( J:114552 )

♀N • unlike hemizygous mutant males most of which exhibit early death at 2-4 months of age, heterozygous mutant females display a normal life span

♀N • testosterone-treated heterozygous mutant females show survival rates similar to those of wild-type, untreated or vehicle-treated control females

behavior/neurological

decreased grip strength ( J:114552 )

♀ • at 16 months of age, testosterone-treated heterozygous mutant females display a small but significant deficit in forelimb grip strength but unchanged body mass relative to vehicle-treated control females

homeostasis/metabolism

increased circulating testosterone level ( J:114552 )

♀ • at 4-7 months of age, testosterone-treated heterozygous mutant females show significantly increased serum testosterone levels relative to vehicle-treated and wild-type control females

increased urine major urinary protein level ( J:114552 )

♀ • testosterone-treated heterozygous mutant females excrete higher levels of major urinary proteins than vehicle-treated control females

muscle

muscle weakness ( J:114552 )

♀ • heterozygous mutant females develop androgen-dependent neuromuscular weakness in the absence of early death

renal/urinary system

increased urine major urinary protein level ( J:114552 )

♀ • testosterone-treated heterozygous mutant females excrete higher levels of major urinary proteins than vehicle-treated control females

growth/size/body

growth/size/body region phenotype ( J:114552 )

♀N • at 16 months of age, testosterone-treated heterozygous mutant females display body weights similar to those of vehicle-treated control females